Regulation of vasculogenesis by platelet-mediated recruitment of bone marrow-derived cells.
Rafii DC. et al, (2008), Arterioscler Thromb Vasc Biol, 28, 217 - 222
A phase I first-in-human study of the polo-like kinase 1-selective inhibitor, GSK461364, in patients with advanced solid tumors
Blagden S. et al, (2008), EJC SUPPLEMENTS, 6, 135 - 136
Characterization of BI 6727, a novel Polo-like kinase inhibitor with a distinct pharmacokinetic profile and efficacy in a model of taxane-resistant colon cancer
Blagden S. et al, (2008), EJC SUPPLEMENTS, 6, 135 - 135
Conflicting data on the prognostic significance of FLT3/TKD mutations in acute myeloid leukemia might be related to the incidence of biallelic disease [Letter]
Mead AJ. et al, (2008), Blood, 112, 444 - 445
Patterns of relapse in patients treated with surgery followed by platinum based chemotherapy for advanced epithelial ovarian cancer
Tuthill MH. et al, (2008), JOURNAL OF CLINICAL ONCOLOGY, 26
The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia
Gale RE. et al, (2008), Blood, 111, 2776 - 2784
A phase I and pharmacokinetic study of lapatinib in combination with infusional 5-fluorouracil, leucovorin and irinotecan.
Midgley RS. et al, (2007), Ann Oncol, 18, 2025 - 2029
Granulocyte and erythropoietic stimulating proteins after high-dose chemotherapy for myeloma.
Littlewood TJ. and Collins GP., (2007), Bone Marrow Transplant, 40, 1147 - 1155
Phase I study of nemorubicin hydrochloride (nemorubicin), a novel DNA-intercalator, in combination with cisplatin in patients with unresectable hepatocellular carcinoma (HCC)
Izzo F. et al, (2007), MOLECULAR CANCER THERAPEUTICS, 6, 3380S - 3380S
Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura.
Bussel JB. et al, (2007), N Engl J Med, 357, 2237 - 2247
A phase Ib study of pertuzumab, a recombinant humanised antibody to HER2, and docetaxel in patients with advanced solid tumours.
Attard G. et al, (2007), Br J Cancer, 97, 1338 - 1343
Comparison of platelet function and bleeding in thrombocytopenic patients with immune thrombocytopenic purpura (ITP) and chemotherapy-induced thrombocytopenia (CIT)
Psaila B. et al, (2007), BLOOD, 110, 624A - 624A
In vivo effects of eltrombopag on human platelet function
Psaila B. et al, (2007), BLOOD, 110, 391A - 392A
The therapeutic potential of O6-alkylguanine DNA alkyltransferase inhibitors.
Khan O. and Middleton MR., (2007), Expert Opin Investig Drugs, 16, 1573 - 1584
Immune thrombocytopenic purpura.
Psaila B. and Bussel JB., (2007), Hematol Oncol Clin North Am, 21, 743 - vii
MORC4, a novel member of the MORC family, is highly expressed in a subset of diffuse large B-cell lymphomas.
Liggins AP. et al, (2007), Br J Haematol, 138, 479 - 486
The immune thrombocytopenic purpura (ITP) bleeding score: assessment of bleeding in patients with ITP.
Page LK. et al, (2007), Br J Haematol, 138, 245 - 248
A phase I trial of lomeguatrib and irinotecan in metastatic colorectal cancer
Sabharwal A. et al, (2007), JOURNAL OF CLINICAL ONCOLOGY, 25